RXRX Recursion Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RXRX

Price (delayed)

$8.84

Market cap

$2.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.58

Enterprise value

$1.73B

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients ...

Highlights
Recursion Pharmaceuticals's gross profit has soared by 124% YoY but it has decreased by 48% from the previous quarter
The gross margin has surged by 121% year-on-year but it has declined by 44% since the previous quarter
Recursion Pharmaceuticals's net income has decreased by 37% YoY and by 12% from the previous quarter
The company's EPS fell by 16% YoY and by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.recursionpharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of RXRX
Market
Shares outstanding
234.65M
Market cap
$2.07B
Enterprise value
$1.73B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.13
Price to sales (P/S)
41.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
38.82
Earnings
Revenue
$44.58M
EBIT
-$332.13M
EBITDA
-$299.66M
Free cash flow
-$299.74M
Per share
EPS
-$1.58
Free cash flow per share
-$1.44
Book value per share
$2.14
Revenue per share
$0.21
TBVPS
$2.72
Balance sheet
Total assets
$653.7M
Total liabilities
$190.26M
Debt
$50.67M
Equity
$463.44M
Working capital
$344.97M
Liquidity
Debt to equity
0.11
Current ratio
4.7
Quick ratio
4.27
Net debt/EBITDA
1.15
Margins
EBITDA margin
-672.3%
Gross margin
4.5%
Net margin
-736%
Operating margin
-785.3%
Efficiency
Return on assets
-50.9%
Return on equity
-72.9%
Return on invested capital
-302.5%
Return on capital employed
-59.3%
Return on sales
-745.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RXRX stock price

How has the Recursion Pharmaceuticals stock price performed over time
Intraday
0.57%
1 week
8.87%
1 month
-1.01%
1 year
71.32%
YTD
-10.34%
QTD
-11.33%

Financial performance

How have Recursion Pharmaceuticals's revenue and profit performed over time
Revenue
$44.58M
Gross profit
$1.99M
Operating income
-$350.06M
Net income
-$328.07M
Gross margin
4.5%
Net margin
-736%
Recursion Pharmaceuticals's gross profit has soared by 124% YoY but it has decreased by 48% from the previous quarter
The gross margin has surged by 121% year-on-year but it has declined by 44% since the previous quarter
Recursion Pharmaceuticals's operating income has decreased by 42% YoY and by 12% QoQ
Recursion Pharmaceuticals's net income has decreased by 37% YoY and by 12% from the previous quarter

Growth

What is Recursion Pharmaceuticals's growth rate over time

Valuation

What is Recursion Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.13
P/S
41.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
38.82
The company's EPS fell by 16% YoY and by 9% QoQ
RXRX's price to book (P/B) is 14% higher than its last 4 quarters average of 3.6
RXRX's equity is up by 6% since the previous quarter but it is down by 4.6% year-on-year
RXRX's price to sales (P/S) is 19% higher than its last 4 quarters average of 34.5
RXRX's revenue is up by 12% year-on-year but it is down by 6% since the previous quarter

Efficiency

How efficient is Recursion Pharmaceuticals business performance
RXRX's ROIC has shrunk by 84% YoY and by 6% QoQ
Recursion Pharmaceuticals's return on assets has decreased by 45% YoY and by 14% QoQ
Recursion Pharmaceuticals's return on equity has decreased by 37% YoY and by 14% QoQ
The company's return on sales fell by 24% YoY and by 21% QoQ

Dividends

What is RXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RXRX.

Financial health

How did Recursion Pharmaceuticals financials performed over time
The quick ratio has declined by 23% year-on-year but it has grown by 2.4% since the previous quarter
The company's current ratio fell by 17% YoY but it rose by 8% QoQ
The debt is 89% smaller than the equity
RXRX's debt to equity is up by 10% year-on-year but it is down by 8% since the previous quarter
RXRX's equity is up by 6% since the previous quarter but it is down by 4.6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.